. . . "18"^^ . . . . "2020-06-22T00:00:00Z"^^ . . . . . . "700"^^ . . . . . . . . . . . . . . . "To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine"@en . . . . . . . . "A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine."@en . . "2018-10-08T00:00:00Z"^^ . . . . . . "To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine"@en . "klinisch onderzoek"@nl . . . "clinical trial"@en . "To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine"@en . . . "80"^^ . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . "ensayu cl\u00EDnicu"@ast . . . . . "NCT03700320" . . .